Two of the biggest drugmakers in the HIV space are teaming up on a combination therapy that has the potential to be a game-changer for patients diagnosed with the dangerous virus for which there is no known cure.
Gilead Sciences inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.
Novavax Inc. said the company’s coronavirus vaccine was 89.3% effective in preventing Covid-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis.
Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca has been on their Covid-19 vaccine efforts, and here is a look at what else is going on with these companies.
The U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva as the only complete long-acting regimen for the treatment of HIV-1 infection in adults.
Topline results from Gilead Sciences’ Phase II/III CAPELLA trial show that treatment with the company’s long-acting HIV-1 capsid inhibitor lenacapavir reduces HIV viral load better than placebo in heavily treated patients living with multidrug resistant HIV-1 infection.
The U.S. Food and Drug Administration granted various designations for Sanofi’s avalglucosidase alfa for Pompe disease, Sanofi’s rilzabrutinib for immune thrombocytopenia, and ViiV Healthcare’s cabotegravir for HIV prevention.
ViiV Healthcare announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of data from the HIV Prevention Trials Network 084 trial of the investigational, long-acting injectable cabotegravir for HIV prevention in women.
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every two months is 89% more effective than daily pills in preventing HIV acquisition in women Findings follow data from HPTN 083, a partner HIV prevention […]
Timothy Ray Brown, the first person known to be cured of HIV when he had a unique type of bone marrow transplant, died in California after relapsing with cancer.